ArticleChina CDC weekly2026
Two mRNA Platforms for Canine Rabies Vaccines: Advances, Limitations, and Field Application Prospects.
Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine rabies control in rural China faces logistical barriers such as multi-dose schedules, cold-chain requirements, and the recapture of free-roaming dogs, which impede progress toward 70% vaccination coverage. Although inactivated vaccines remain the cornerstone of rabies control, mRNA platforms offer both manufacturing and immunological advantages. This review compares non-replicating mRNA (nr-mRNA) and self-amplifying mRNA (saRNA) platforms. It also examines oral and vectored vaccines as comparators for free-roaming dogs beyond the reach of injectable products. LVRNA001 and ABO1005 are nr-mRNA candidates that provide complete protection in canine challenge models using two-dose regimens; neutralizing antibody geometric mean titers (GMTs) exceed the World Health Organization (WHO) 0.5 IU/mL threshold through day 125, with the LVRNA001 50-μg group reaching approximately 100 IU/mL versus approximately 16 IU/mL for the inactivated vaccine (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.